Can-Fite BioPharma Ltd.
Reinhold Cohn House
P.O.Box: 4060
Tel Aviv
Tel: 03-7109330
Fax: 03-5606405
Email: dieliasoof@rcip.co.il
419 articles about Can-Fite BioPharma Ltd.
-
Can-Fite Reports on Progress With Its Namodenoson NASH Program
12/14/2020
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver di
-
Can-Fite to Present at Benzinga Global Small Cap Conference on December 8, 2020
12/3/2020
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the Company’s CEO Dr. Pnina Fishman will present at Benzinga’s inaugural Global SmallCap Conference on Tuesday, December 8, 2020 at 3:00 pm ET on Track 2. Investors interested in viewing Can-Fite’s prese
-
Can-Fite Reports Third Quarter 2020 Financial Results & Provides Clinical Update
11/30/2020
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the nine months ended September 30, 2020. This press release features multimedia. View the full rel
-
Can-Fite’s Namodenoson Abstract Selected as ‘Best of The Liver Meeting’ in the NASH Category of the American Association of Liver Diseases (AASLD)
11/24/2020
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that following a late-breaking oral presentation of its Phase II Namodenoson study in the treatment of NAFLD/NASH delivered at the American Association for the Study of Liver Diseases (AASLD) conference, the
-
Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET
11/23/2020
Can-Fite BioPharma Ltd. announced it will conduct a conference call with investors to review financial results for its third quarter ended September 30, 2020, and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson.
-
Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference
11/16/2020
Dr. Safadi, the study’s Principal Investigator: “Namodenoson’s very impressive study data may result in a promising drug for the treatment of NAFLD/NASH due to the combination of good efficacy and favorable safety.”
-
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020
11/9/2020
Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6 th Annual Israel Conference on November 12, 2020
-
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020
10/13/2020
Can-Fite BioPharma Ltd. announced it will host a conference call with investors to provide an update on its Phase III psoriasis study and the positive interim data analysis and recommendations from the study’s Independent Data Monitoring Committee.
-
Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis
10/6/2020
Independent Data Monitoring Committee (IDMC) conducted a pre-planned interim analysis of the Company’s Phase III Comfort™ trial of Piclidenoson for the treatment of psoriasis and recommended to continue with this psoriasis study A separate IDMC for the pre-planned interim analysis of the Acrobat™ Rheumatoid Arthritis (RA) Phase III study recommended not to continue this study. The Company plans to undertake a detailed analysis of the data of the
-
Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference
9/30/2020
Principal Investigator Prof. Rifaat Safadi to present Namodenoson’s Phase II results at highly prestigious scientific conference for liver diseases
-
Can-Fite to Participate in Two BioPharma Partnering Conferences
9/22/2020
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the Company’s VP of Business Development, Dr. Sari Fishman, is participating in two conferences where she will conduct one-on-one meetings with pharmaceutical companies for potential distribution and partne
-
Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020
9/8/2020
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the Company’s CEO Dr. Pnina Fishman will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 2:00 pm ET in Room 6.
-
FDA Clears Can-Fite to Commence Phase II COVID-19 Study
8/31/2020
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the U.S. Food and Drug Administration (FDA) has issued a “safe to proceed” notice for Can-Fite’s Investigational N
-
Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update
8/27/2020
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced financial results for the six months ended June 30, 2020.
-
Can-Fite to Present at The LD Micro 500 Virtual Conference on September 1, 2020
8/26/2020
Can-Fite BioPharma Ltd. today announced that it will be presenting at the 12th annual LD 500 on Tuesday, September 1, 2020 at 9:20 AM EST / 6:20 AM PST.
-
Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET
8/20/2020
Can-Fite BioPharma Ltd. announced it will conduct a conference call with investors to review financial results of its second quarter and provide an update on clinical and corporate developments, including its advanced stage drug candidates Piclidenoson and Namodenoson.
-
Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study
7/27/2020
Can-Fite BioPharma Ltd. announced today that it has submitted an Investigational New Drug (IND) application to U.S. Food and Drug Administration (FDA) for a Phase II study of its lead drug candidate Piclidenoson in the treatment of COVID-19. The IND application is based on feedback and guidance from the FDA from prior pre-IND advice.
-
Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly
7/15/2020
Piclidenoson to be evaluated for the treatment of COVID-19 infected patients with moderate symptoms
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
-
Can-Fite Announces $3.4 Million Registered Direct Offering
7/6/2020
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,705,500 of the Company’s American Depositary Shares (ADSs), at a purchase price